





Transforming Treatment of High-Risk Mveloma

Network includes Tisch Cancer Center at Mt Sinai, Albert Einstein Medical College, Hackensack University Medical Center, Stanford University Medical Center, UCSF, Washington University of Saint Louis



A Systems Biology Approach to High-Risk Myeloma

Network includes Erasmus Medical Center, Rotterdam; Amsterdam University Medical Centers; Julius Maximilian University of Wurzburg; University of Turin; University of Salamanca

MM RF Each network will receive \$7M over 3 years for a total \$21M investment by the MMRF, meant to foster collaboration and advance compelling hypotheses that are ready for rapid testing in clinical trials.



Clinical and Multi-Omics Platforms to Define High-Risk Smoldering Myeloma

Network includes Emory University, Atrium Health Levine Cancer Institute, Icahn School of Medicine at Mt. Sinai, Mass General Hospital, Mayo Clinic, MSKC Institute, Dana-Farber Cancer Institute

Sagar Lonial, MD

MMRF 2023 Scholars Grant Awardees

Eden Biltibo

Vanderbilt University Medical Center

Grant Proposal:



Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing

Frequent hospital visits cost money and increases exposure to bad bugs. If we prove every 8-week daratumumab works as good, patients won't have to come to the hospital on a monthly basis.

Eden Biltibo, MD, MS is a Hematology/Oncology clinical fellow at Vanderbilt University Medical Center., who is passionate about developing strategies to bridge health care disparities in Multiple Myeloma care. She particularly focuses on the equitable utilization of immunotherapeutics in multiple myeloma and improving racial diversity of clinical trial participants in those trials.

Joselle Cook Mayo Clinic, Rochester



Prevalence Of MGUS Among Unique Populations Of Black People

For people who test positive for MGUS, we will perform DNA testing which will inform us about ancestral origins and will give information on genetic variations that we know are associated with MGUS and MM.

Joselle Cook, MBBS is an assistant professor and Hematology/Oncology Fellow at Mayo Rochester. Dr. Cook received her medical degree from University of the West Indies Faculty of Medical Sciences. She completed her residency and fellowship training in 2022.


Speakers


Amy Blake, NP-C Karmanos Cancer Institute Detroit, Michigan


Craig Emmitt Cole, MD

Wayne State University Karmanos Cancer Institute Detroit, Michigan

Michigan State University College of Human Medicine Karmanos Cancer Institute East Lansing, Michigan













 Confirms the type of myeloma or precursor condition



- Confirms diagnosis of myeloma
- Determines how advanced the myeloma or precursor condition is



- Detects the presence and extent of bone disease and the presence of myeloma outside of the bone marrow



Understanding Your Labs! Complete Blood Count (CBC) Normal Range

Sample	Blood		
What is measured	The level of hemoglobin and the number of red blood cells, white blood cells, and platelets		
Component*		Normal range [†]	
Red blood cells		Women: 3.90 to 5.03×10^{12} /L Men: 4.32 to 5.72×10^{12} /L	
Hemoglobin		Women: 12.1 to 15.1 g/dL Men: 13.8 to 17.2 g/dL	
White blood cells		Total: 3.5 to $10.5 \times 10^{9}/L$ Neutrophils (as absolute neutrophil count [ANC]): 1.7 to $7.0 \times 10^{9}/L$ Monocytes: 0.2 to $1.0 \times 10^{9}/L$ Lymphocytes: 1.0 to $3.0 \times 10^{9}/L$	
Platelets		150 to 450×10^{9} /L	

*Additional components not listed here may be analyzed, but they are not typically used for diagnosing or managing myeloma.

[†]Normal ranges vary slightly from one institution to another.

		<u> </u>	′our Labs! ic Panel (CMP) Normal R	ange
	Sample	Blood		
	What is measured	Levels	of electrolytes, albumin, calcium, BUN, and creatinine	
	Component*		Normal range [†]	
	Albumin		3.4 to 5.4 g/dL	
	BUN (blood urea nitrogen)		6 to 20 mg/dL	
	Calcium		8.5 to 10.2 mg/dL	
	Chloride		96 to 106 mEq/L	
	Creatinine Potassium		0.6 to 1.3 mg/dL	
			3.7 to 5.2 mEq/L	
	Sodium		135 to 145 mEq/L	

*Additional components not listed here may be analyzed, but they are not typically used for diagnosing or managing myeloma.

*Normal ranges vary slightly from one institution to another.


Understanding Your Labs! Serum Protein Electrophoresis (SPEP) Normal Range


Sample	Blood	
What is measured	M prot	ein
Component		Normal range*
Albumin		3.8 to 5 g/dL
Alpha-1		0.1 to 0.3 g/dL
Alpha-2		0.6 to 1 g/dL
Beta		0.7 to 1.4 g/dL
Gamma		0.7 to 1.6 g/dL
M protein		0


*Normal ranges vary slightly from one institution to another.

What is measuredLevels of light chainsComponentNormal range*Kappa (κ) free light chains3.3 to 19.4 mg/LLambda (Λ) free light chains5.71 to 26.3 mg/LRatio of kappa (κ)/lambda (Λ)0.26 to 1.65
Kappa (κ) free light chains3.3 to 19.4 mg/LLambda (λ) free light chains5.71 to 26.3 mg/L
Ratio of kappa (κ)/lambda (λ) 0.26 to 1.65
*Normal ranges vary slightly from one institution to another.












Blood, Urine, Bone Marrow, and Imaging Tests Used to Identify MGUS, SMM, or Active Multiple Myeloma Marker Measured MGUS SMM Active MM ≥3 g/dL in blood or ≥3 g/dL in blood or M protein <3 g/dL in blood ≥500 mg/24 hrs in ≥500 mg/24 hrs in urine urine Plasma cells in <10% ≥10%–60% ≥60% bone marrow **Clinical features** No myeloma-No myeloma-defining ≥1 myeloma-defining event*, defining events* events* including either: ≥1 CRAB feature or ≥1 SLiM feature *CRAB, calcium elevation, renal insufficiency, anemia, bone disease; SLiM, >60% plasma cells in bone marrow, free light chain involved to uninvolved ratio >100, >1 focal lesion on MRI


21


Rajkumar SV et al. Lancet Oncol. 2014;15:e538.


















- Genetic changes in myeloma cells may affect prognosis and treatment selection
- Using samples from the bone marrow—specific tests look at these genetic changes
- Some tests are used routinely and look at the *chromosomal* changes (FISH)
- Newer tests assess changes in the DNA (gene expression profiling and next-generation sequencing)
 - Ask your doctor if these tests are available
- All patients in the MMRF CoMMpass study had genomic sequencing from diagnosis to relapse. The resulting data provides detailed genetic profiles for every myeloma patient at every stage of their disease!

































<text><list-item><list-item><list-item>
























Myeloma Mentors[®] allows patients and caregivers the opportunity to connect with trained mentors. This is a phone-based program offering an opportunity for a patient and/or caregiver to connect one-on-one with a trained patient and/or caregiver mentor to share his or her myeloma journeys and experiences.

No matter what your disease state—smoldering, newly diagnosed, or relapsed/ refractory—our mentors have insights and information that can be beneficial to both patients and their caregivers.

Contact the Patient Navigation Center at 888-841-6673 to be connected to a Myeloma Mentor or to learn more.




Upcoming Patient Education Events Save the Date

Program	Date and Time	Speakers
Understanding Lab Report FAQs	Friday, June 7, 2024	Joshua Richter, MD
<i>Livestream</i>	3:00 рм	Michelle Lyn, NP

For more information or to register, visit **themmrf.org/educational-resources**





Need help with travel to a clinical study?

- The MMRF has partnered with the Lazarex Cancer Foundation to help provide more equitable access to clinical studies for multiple myeloma patients
- This partnership is one facet of the MMRF's commitment to improve diversity and representation in myeloma clinical studies
- MMRF has provided \$100,000 over 2 years to Lazarex to fund travel, lodging, and food for patients (and a travel companion) so that they can participate in clinical studies that are appropriate for them
- Patients are funded according to income guidelines and will be reimbursed for allowed expenses
- For more information on this program and to be connected with Lazarex, call our Patient Navigation Center at 1-888-841-6673





